Form 8-K Viking Therapeutics, For: Sep 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Form 8-K Viking Therapeutics, For: Sep 18
September 18, 2018 3:39 PM EDT
SunTrust Robinson Humphrey analyst Edward Nash raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating.
Nash commented, "Viking announced promising results from a Phase II study of VK2809 in NAFLD/hypercholesterolemia. 12-week treatment... More
September 18, 2018 12:31 PM EDT
Maxim Group analyst Jason McCarthy raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $28.00 (from $14.00) while maintaining a Buy rating. The new price target matches a Street High.
The analyst highlights:
VKTX shares are up sharply (~+80%) after announcing positive top-line 12-week P2 data for VK2809, an oral thyroid beta receptor agonist (TR), in Non-Alcoholic Fatty...
More
September 18, 2018 11:57 AM EDT
H.C. Wainwright analyst Joseph Pantginis raised the price target on Viking Therapeutic (NASDAQ: VKTX) to a 'Street High' $28.00 (from $15.00) while maintaining a Buy rating.
The analsyt commented, "This morning, the highly anticipated VK2809 top-line data in non-alcoholic fatty liver disease (NAFLD) and... More
September 18, 2018 7:37 AM EDT
Viking Therapeutics (NASDAQ: VKTX) Climbs 140% After Shares Resume Trading
...
More
